$8.21
8.03% today
Nasdaq, Sep 16, 08:19 pm CET
ISIN
US75943R1023
Symbol
RLAY
Sector
Industry

Relay Therapeutics Inc Stock price

$7.60
+1.04 15.85% 1M
-1.54 16.85% 6M
-3.41 30.97% YTD
-1.89 19.92% 1Y
-28.10 78.71% 3Y
-27.45 78.32% 5Y
-27.45 78.32% 10Y
Nasdaq, Closing price Fri, Sep 13 2024
-0.02 0.26%
ISIN
US75943R1023
Symbol
RLAY
Sector
Industry

Key metrics

Market capitalization $1.02b
Enterprise Value $380.24m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 10.80
P/S ratio (TTM) P/S ratio 28.90
P/B ratio (TTM) P/B ratio 1.49
Revenue growth (TTM) Revenue growth 3,637.69%
Revenue (TTM) Revenue $35.21m
EBIT (operating result TTM) EBIT $-373.37m
Free Cash Flow (TTM) Free Cash Flow $-283.24m
Cash position $688.42m
EPS (TTM) EPS $-2.52
P/E forward negative
P/S forward 100.14
EV/Sales forward 37.42
Short interest 8.67%
Show more

Is Relay Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,912 stocks worldwide.

Relay Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a Relay Therapeutics Inc forecast:

12x Buy
92%
1x Hold
8%

Analyst Opinions

13 Analysts have issued a Relay Therapeutics Inc forecast:

Buy
92%
Hold
8%

Financial data from Relay Therapeutics Inc

Jun '24
+/-
%
Net Profit -323 -323
6% 6%
-917%
Depreciation and Amortization 5.50 5.50
16% 16%
16%
Stock Compensation 95 95
31% 31%
270%
Operating Cash Flow -281 -281
8% 8%
-797%
Investments 2.50 2.50
68% 68%
7%
Dividend Paid - -
-
-
Free Cash Flow -283 -283
6% 6%
-804%

In millions USD.

Don't miss a Thing! We will send you all news about Relay Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Relay Therapeutics Inc Stock News

Negative
The Motley Fool
5 days ago
The biotech firmed up the details of its upcoming secondary share issue. However, the flotation will be dilutive to existing shareholders.
Positive
Seeking Alpha
5 days ago
Relay Therapeutics' Dynamo platform combines machine learning and physics-based simulation to target dynamic protein conformations for oncology and genetic disease therapies. RLY-2608 targets PI3Kα-mutated HR+/HER2- breast cancer, with promising Phase 2 results and potential approval by 2026-2027. The company's RLY-4008 targets FGFR2-altered cholangiocarcinoma, and it is seeking pivotal trials ...
Neutral
GlobeNewsWire
6 days ago
CAMBRIDGE, Mass., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, announced today the pricing of an underwritten public offering of 28,571,429 shares of its common stock at a public offering price of $7.00 per share.
More Relay Therapeutics Inc News

Company Profile

Relay Therapeutics, Inc. is a clinical-stage precision medicines company. It focuses on using innovative experimental and computational approaches on protein motion for making medicines against intractable precision medicine targets. The company was founded by David Elliot Shaw, Matthew P. Jacobson, Dorothee Kern, Mark Murcko, Alexis Borisy, and Jakob Loven on May 4, 2015 and is headquartered in Cambridge, MA.

Head office United States
CEO Sanjiv Patel
Employees 323
Founded 2015
Website www.relaytx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today